215 related articles for article (PubMed ID: 8834891)
1. In vitro bactericidal and in vivo therapeutic activities of a new rifamycin derivative, KRM-1648, against Mycobacterium tuberculosis.
Yamamoto T; Amitani R; Suzuki K; Tanaka E; Murayama T; Kuze F
Antimicrob Agents Chemother; 1996 Feb; 40(2):426-8. PubMed ID: 8834891
[TBL] [Abstract][Full Text] [Related]
2. Activity of KRM-1648, a new benzoxazinorifamycin, against Mycobacterium tuberculosis in a murine model.
Klemens SP; Grossi MA; Cynamon MH
Antimicrob Agents Chemother; 1994 Oct; 38(10):2245-8. PubMed ID: 7840552
[TBL] [Abstract][Full Text] [Related]
3. Activity of KRM-1648 alone or in combination with both ethambutol and kanamycin or clarithromycin against Mycobacterium intracellulare infections in beige mice.
Yamamoto T; Amitani R; Suzuki K; Tanaka E; Murayama T; Kuze F
Antimicrob Agents Chemother; 1996 Feb; 40(2):429-32. PubMed ID: 8834892
[TBL] [Abstract][Full Text] [Related]
4. Activity of KRM-1648 in combination with isoniazid against Mycobacterium tuberculosis in a murine model.
Klemens SP; Cynamon MH
Antimicrob Agents Chemother; 1996 Feb; 40(2):298-301. PubMed ID: 8834869
[TBL] [Abstract][Full Text] [Related]
5. Activity of KRM 1648 alone or in combination with ethambutol or clarithromycin against Mycobacterium avium in beige mouse model of disseminated infection.
Bermudez LE; Kolonoski P; Young LS; Inderlied CB
Antimicrob Agents Chemother; 1994 Aug; 38(8):1844-8. PubMed ID: 7986018
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo activities of the benzoxazinorifamycin KRM-1648 against Mycobacterium tuberculosis.
Hirata T; Saito H; Tomioka H; Sato K; Jidoi J; Hosoe K; Hidaka T
Antimicrob Agents Chemother; 1995 Oct; 39(10):2295-303. PubMed ID: 8619585
[TBL] [Abstract][Full Text] [Related]
7. [Studies on therapeutic efficacy of a new anti-tuberculous drug, benzoxazinorifamycin, against murine experimental mycobacterial infections: attempt at various regimens and protocols].
Tomioka H; Saito H
Kekkaku; 1994 Nov; 69(11):703-10. PubMed ID: 7837724
[TBL] [Abstract][Full Text] [Related]
8. [Therapeutic efficacy of benzoxazinorifamycin KRM-1648 against experimental murine tuberculosis: (1). A study on the efficacy of short course treatment with the intratracheal and intravenous infection model].
Doi N
Kekkaku; 1998 Feb; 73(2):53-64. PubMed ID: 9545697
[TBL] [Abstract][Full Text] [Related]
9. Immunodeficiency and Intermittent Dosing Promote Acquired Rifamycin Monoresistance in Murine Tuberculosis.
Park SW; Tasneen R; Converse PJ; Nuermberger EL
Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28874368
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapeutic activity of benzoxazinorifamycin, KRM-1648, against Mycobacterium tuberculosis in C57BL/6 mice.
Reddy MV; Luna-Herrera J; Daneluzzi D; Gangadharam PR
Tuber Lung Dis; 1996 Apr; 77(2):154-9. PubMed ID: 8762850
[TBL] [Abstract][Full Text] [Related]
11. Activities of the benzoxazinorifamycin KRM 1648 and ethambutol against Mycobacterium avium complex in vitro and in macrophages.
Inderlied CB; Barbara-Burnham L; Wu M; Young LS; Bermudez LE
Antimicrob Agents Chemother; 1994 Aug; 38(8):1838-43. PubMed ID: 7986017
[TBL] [Abstract][Full Text] [Related]
12. In vitro activity of the benzoxazinorifamycin KRM-1648 against drug-susceptible and multidrug-resistant tubercle bacilli.
Luna-Herrera J; Reddy MV; Gangadharam PR
Antimicrob Agents Chemother; 1995 Feb; 39(2):440-4. PubMed ID: 7726512
[TBL] [Abstract][Full Text] [Related]
13. Bacteriostatic and bactericidal activities of benzoxazinorifamycin KRM-1648 against Mycobacterium tuberculosis and Mycobacterium avium in human macrophages.
Mor N; Simon B; Heifets L
Antimicrob Agents Chemother; 1996 Jun; 40(6):1482-5. PubMed ID: 8726023
[TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo antibacterial activities of KRM-1648 and KRM-1657, new rifamycin derivatives.
Fujii K; Tsuji A; Miyazaki S; Yamaguchi K; Goto S
Antimicrob Agents Chemother; 1994 May; 38(5):1118-22. PubMed ID: 8067748
[TBL] [Abstract][Full Text] [Related]
15. [In vitro activities of benzoxazinorifamycin KRM-1648 against Mycobacterium tuberculosis].
Sato K; Tomioka H; Saito H; Kawahara S; Hidaka T
Kekkaku; 1996 Aug; 71(8):459-64. PubMed ID: 8831191
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of rifalazil in a combination treatment regimen as an alternative to isoniazid-rifampin therapy in a mouse tuberculosis model.
Lenaerts AM; Chase SE; Cynamon MH
Antimicrob Agents Chemother; 2000 Nov; 44(11):3167-8. PubMed ID: 11036043
[TBL] [Abstract][Full Text] [Related]
17. Comparative antimycobacterial activities of rifampin, rifapentine, and KRM-1648 against a collection of rifampin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations.
Moghazeh SL; Pan X; Arain T; Stover CK; Musser JM; Kreiswirth BN
Antimicrob Agents Chemother; 1996 Nov; 40(11):2655-7. PubMed ID: 8913484
[TBL] [Abstract][Full Text] [Related]
18. Accumulation of KRM-1648 by Mycobacterium aurum and Mycobacterium tuberculosis.
Piddock LJ; Ricci V
J Antimicrob Chemother; 2000 May; 45(5):681-4. PubMed ID: 10797093
[TBL] [Abstract][Full Text] [Related]
19. Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis.
Rosenthal IM; Tasneen R; Peloquin CA; Zhang M; Almeida D; Mdluli KE; Karakousis PC; Grosset JH; Nuermberger EL
Antimicrob Agents Chemother; 2012 Aug; 56(8):4331-40. PubMed ID: 22664964
[TBL] [Abstract][Full Text] [Related]
20. Relationship between antimycobacterial activities of rifampicin, rifabutin and KRM-1648 and rpoB mutations of Mycobacterium tuberculosis.
Yang B; Koga H; Ohno H; Ogawa K; Fukuda M; Hirakata Y; Maesaki S; Tomono K; Tashiro T; Kohno S
J Antimicrob Chemother; 1998 Nov; 42(5):621-8. PubMed ID: 9848446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
